Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13 juin 2024 08h00 HE
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
CARGO Therapeutics to Participate in Upcoming Investor Conferences
28 mai 2024 08h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
28 mai 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 mars 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
13 déc. 2023 16h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Announces Scientific Advisory Board
06 déc. 2023 08h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
23 nov. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
21 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...